Facial skin has distinct features compared to other body regions, and its layers undergo critical changes with aging and stress. These alterations contribute to cosmetic concerns such as dark circles, under-eye fluid accumulation, and loss of firmness. Current in vitro models often fail to reproduce facial area-specific characteristics, including 3D vascular network, extracellular matrix (ECM) responses, and the supporting hypodermal layer. This limits accurate cosmetic evaluation.
To address these gaps, we characterized 3D ex vivo vascularized human tissue models derived from different subcutaneous body sites to identify site-specific characteristics relevant for skincare development.
Our presentation in the “New Tools” session showcased 3D vascularized ex vivo human tissue models derived from facial and abdominal areas. These models reveal critical body-site-specific differences in tissue energy metabolism, vascular/lymphatic networks, and extracellular matrix composition, key factors for precise dermo-cosmetic ingredient evaluation.
Abdominal tissues showed higher metabolic activity, whereas facial tissues exhibited specific ECM gene expression and protein secretion profiles known to be altered during aging, consistent with distinct biological roles. Additionally, by mimicking aging-related changes, such as reduced procollagen Iα secretion, we induced a facial-like phenotype in abdominal-derived models
Our approach contributes to the reduction of animal use by offering advanced, human‑based models that align with evolving regulatory expectations and societal demand for more ethical testing strategies.
By capturing distinct features of tissue energy metabolism, vascular and lymphatic networks, and extracellular matrix remodeling, our models support the design of targeted, site‑relevant claims for products addressing dark circles, under‑eye bags, firmness, elasticity, cellulite, and visible signs of aging.
Follow us on LinkedIn for updates and insights from the event, and visit the official website for more information: https://www.sfcosmeto.fr/nos-evenements/symposium/
ExAdEx-Innov contributes to a publication on adipose tissue processing ExAdEx-Innov is proud to contribute to a new collaborative study published in Scientific Reports, a journal
EXADEX-INNOV is excited to announce that Resalis Therapeutics will present preclinical translational data at Obesity Week 2025, including results obtained on our human adipose tissue
Our journey as part of the French biotech delegation during the Nordic Biotech Mission, organized by Business France Nordics and Bpifrance in Sweden and Denmark,
Copyright © 2022 ExAdEx-Innov All rights reserved
KOL on adipose tissue biology.
Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice).
Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program).
Co-inventor of 5 patents
Expert in clinical applications of adipose tissue.
Plastic Reconstructive and Aesthetic Surgeon in Nice.
Member of the Medical Council of Alpes Maritimes region.
Expert for the French National Regulatory Agency ANSM for medical devices.
Certified by French Health Autority HAS (2020-2024).
PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.
Expert in cell therapy and immunology.
Senior Lecturer (Maitre de conférences).
Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).
Director of « Micoralis » research team at Université Côte d’Azur (Nice).
Founder and CEO of the biotech company Biointerférence (2003-2006).
Co-inventor of 5 patents.
Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.
With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov.
In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille).
He is co-inventor of the 2 company’s patent families.
Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue.
Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.
With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years.
He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.
Main areas of expertise: Biotech Startup Business Development; Project management
